

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Goldpac Group Limited
金邦達寶嘉控股有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3315)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 18 MAY 2017,
CHANGE OF DIRECTORS
AND
CHANGE OF MEMBERS OF BOARD COMMITTEES**

Reference is made to the circular of Goldpac Group Limited (the “**Company**”) dated 13 April 2017 (the “**Circular**”). Terms used herein shall have the same meanings as defined in the Circular, unless the context requires otherwise.

RESULTS OF THE AGM

At the annual general meeting (the “**AGM**”) of the Company held on 18 May 2017, all the proposed resolutions as set out in the notice of the AGM dated 13 April 2017 were duly passed by the Shareholders by way of poll, except resolution no. 3(iii) in respect of the re-election of Mr. Christophe Jacques PAGEZY as a non-executive Director. The poll results in respect of the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and the auditors of the Company for the year ended 31 December 2016.	604,694,620 99.24%	4,624,000 0.76%

Ordinary Resolutions		Number of Votes (%)	
		For	Against
2.	(i) To declare a final dividend of HK7.0 cents (equivalent to approximately RMB6.2 cents) per ordinary share for the year ended 31 December 2016.	609,318,620 100%	0 0%
	(ii) To declare a special dividend of HK6.0 cents (equivalent to approximately RMB5.3 cents) per ordinary share for the year ended 31 December 2016.	609,318,620 100%	0 0%
3.	(i) To re-elect Mr. LU Run Ting as an executive Director.	584,172,949 95.87%	25,145,671 4.13%
	(ii) To re-elect Mr. LU Runyi as an executive Director.	604,694,620 99.24%	4,624,000 0.76%
	(iii) To re-elect Mr. Christophe Jacques PAGEZY as a non-executive Director.	183,785,527 30.64%	416,056,093 69.36%
	(iv) To appoint Mr. WU Siqiang as an executive Director.	604,694,620 99.24%	4,624,000 0.76%
	(v) To appoint Ms. YE Lu as an independent non-executive Director.	604,694,620 99.24%	4,624,000 0.76%
4.	To authorise the Board to fix the remuneration of the Directors.	604,694,620 99.24%	4,624,000 0.76%
5.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors of the Company and to authorize the Board to fix their remuneration.	604,694,620 99.24%	4,624,000 0.76%
6.	To grant a general mandate to the Board to allot, issue and deal with shares of the Company not exceeding 20% of the number of shares of the Company in issue as at the date of passing of this resolution.	404,554,822 66.39%	204,763,798 33.61%
7.	To grant a general mandate to the Board to buy back shares of the Company not exceeding 10% of the number of shares of the Company in issue as at the date of passing of this resolution.	604,694,620 99.24%	4,624,000 0.76%
8.	To extend the general mandate granted under resolution no. 6 by adding shares bought back pursuant to the general mandate granted under resolution no. 7.	573,628,674 94.14%	35,689,946 5.86%

Notes:

- (a) As a majority of the votes were cast in favour of each of the resolutions nos. 1, 2(i), 2(ii), 3(i), 3(ii), 3(iv), 3(v), 4, 5, 6, 7 and 8, each of these resolutions was duly passed as an ordinary resolution. As a majority of the votes were cast against resolution no. 3(iii), this resolution was not passed as an ordinary resolution at the AGM.
- (b) As at the date of the AGM, the total number of shares of the Company in issue was 833,561,000 shares.
- (c) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 833,561,000 shares.
- (d) There were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Listing Rules.
- (e) No Shareholder was required under the Listing Rules to abstain from voting on the resolutions at the AGM. There was no restriction on Shareholders to cast votes on any of the proposed resolutions at the AGM.
- (f) None of the Shareholders have stated their intention in the Company's circular dated 13 April 2017 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (g) The Company's share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

CHANGE OF DIRECTORS

(a) Retirement of Director

As set out above, Mr. Christophe Jacques PAGEZY was not re-elected at the AGM and thus retired as a non-executive Director with effect from the conclusion of the AGM. As a result of his retirement, Mr. PAGEZY also ceased to be a member of nomination committee of the Company upon the conclusion of the AGM.

The Board is not aware of any disagreement with Mr. PAGEZY or any matter relating to his retirement that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. PAGEZY for his valuable contribution to the Company during his tenure of office.

(b) Resignation of Directors

As set out in the Circular, the following Directors have tendered their resignations to the Company and their resignations took effect at the conclusion of the AGM:

- (i) Mr. TING Tao I has resigned as a non-executive Director and ceased to act as a member of the remuneration committee of the Company as he intends to devote more time to other business commitments; and
- (ii) Mr. ZHU Lijun has resigned as an independent non-executive Director and ceased to act as a member of each of the audit committee and the nomination committee of the Company as he intends to devote more time to his family and personal affairs.

The Board is not aware of any disagreement with any of Mr. TING and Mr. ZHU, or any matter relating to their resignations that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to each of Mr. TING and Mr. ZHU for his valuable contribution to the Company during his tenure of office.

(c) Appointment of Directors

As set out above, since the ordinary resolution no. 3(iv) regarding the appointment of Mr. WU Siqiang (“**Mr. Wu**”) as an executive Director and the ordinary resolution no. 3(v) regarding the appointment of Ms. YE Lu (“**Ms. Ye**”) as an independent non-executive Director were passed as ordinary resolutions at the AGM, the appointment of Mr. Wu as an executive Director and Ms. Ye as an independent non-executive Director took effect after the conclusion of the AGM. Please refer to the Circular for the biographical details of Mr. Wu and Ms. Ye.

The Board is pleased to announce that, Dr. LING Wai Lim (盧威廉博士) (“**Dr. LING**”) has been appointed by the Board as a non-executive Director of the Company after the conclusion of the AGM.

Dr. LING Wai Lim, aged 30, has over 10 years of experience in biomedical research and research project management. The biographical details of Dr. LING are set out as follows:

Dr. LING has been the project manager of China Regenerative Medicine International Limited (Stock Code: 8158), a company listed on the Growth Enterprise Market of the Stock Exchange, since September 2016, in which he served as a project analyst from June 2015 to August 2016. Dr. LING served as a research assistant of The University of Hong Kong, Department of Paediatrics and Adolescent Medicine, from December 2010 to May 2012.

Dr. LING received the Bachelor of Science (Biotechnology) from The University of Hong Kong in 2008, the Master of Philosophy in Microbiology from The University of Hong Kong in 2010, and also the Doctor of Philosophy in Immunology from The University of Hong Kong in 2015.

As at the date of this announcement, Dr. LING directly holds 16,000 Shares. Save as disclosed, Dr. LING does not have, and is not deemed to have any other interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. LING is the son of Mr. LU Run Ting, who is the chairman of the Board, an executive Director and a Controlling Shareholder of the Company. He is also the nephew of Mr. LU Runyi, who is an executive Director and senior vice president of the Company. Save as disclosed above, Dr. LING (i) has no other relationship with any Director, senior management or substantial or Controlling Shareholder of the Company; and (ii) has not held any position with the Company or any of its subsidiaries or any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years.

Dr. LING has entered into a letter of appointment with the Company for a term of three years commencing from the date of AGM until terminated by not less than three months' notice in writing served by either party on the other. Dr. LING shall retire at the next following general meeting and shall then be eligible for re-election in accordance with the Articles of Association. He is subject to retirement and re-election at least once every three years in accordance with the Articles of Association. Dr. LING is entitled to a director's fee in the sum of HK\$198,000 per annum, which is determined with reference to his responsibilities, experience, performance and the prevailing market conditions.

Save as disclosed above, there is no other information relating to Dr. LING that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter which needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to welcome Mr. Wu, Ms. Ye and Dr. LING to the Board.

CHANGE OF MEMBERS OF BOARD COMMITTEES

The Board is pleased to announce that the composition of the Board Committees of the Company has been changed as follows:

- (a) Mr. LU Run Ting has been appointed by the Board as a member of the remuneration committee;
- (b) Mr. HOU Ping has been appointed by the Board as a member of the nomination committee; and
- (c) Ms. YE Lu has been appointed by the Board as a member of the audit committee and nomination committee.

By Order of the Board
Goldpac Group Limited
Mr. LU Run Ting
Chairman

Hong Kong, 18 May 2017

As at the date of this announcement, the executive Directors of the Company are Mr. LU Run Ting, Mr. HOU Ping, Mr. LU Runyi, Mr. LU Xiaozhong and Mr. WU Siqiang; the non-executive Director of the Company is Dr. LING Wai Lim; and the independent non-executive Directors of the Company are Mr. MAK Wing Sum Alvin, Mr. LIU John Jianhua and Ms. YE Lu.